International Active Surveillance Study: Native Estrogen Estetrol (E4) Safety Study

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
AgeNot listed
SponsorCenter for Epidemiology and Health Research, Germany

About this trial

Multinational, comparative, prospective, active surveillance study that follows two cohorts.

The primary objective of the study is to characterize and compare the risks of E4/Drospirenone (DRSP) with levonorgestrel-containing combined oral contraceptives (EE/LNG) in a study population that is representative of the actual users of these preparations. The main clinical outcome of interest is venous thromboembolism (VTE), specifically deep venous thrombosis (DVT) and pulmonary embolism (PE). Secondary objectives include measuring the occurrence of unintended pregnancy, assessing the risk of arterial thromboembolism (ATE), describing the drug utilization pattern, describing the baseline risk profile for VTE and ATE, and investigating outcomes associated with foetal exposure to E4/DRSP.

Eligibility criteria

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

101,000 Participants
are grouped into 2 trial groups

Sponsors and collaborators

Center for Epidemiology and Health Research, Germany

Lead sponsor

Estetra

Collaborator

Gedeon Richter Plc.

Collaborator